MaxCyte MXCT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.65M-7.1% | $7.3M-16.0% | $6.83M-16.4% | $8.51M-18.4% | $10.39M-8.4% | ||
| $1.57M+4.8% | $1.61M-29.4% | $1.6M-17.2% | $1.52M+2.1% | $1.5M+6.7% | ||
| $8.08M-9.1% | $5.69M-11.3% | $5.23M-16.1% | $6.99M-21.8% | $8.89M-10.5% | ||
| 83.7%-1.8pp | 77.9%+4.2pp | 76.6%+0.2pp | 82.1%-3.6pp | 85.6%-2.0pp | ||
| $3.86M-34.7% | $3.34M-27.7% | $5.32M0.0% | $6.27M+11.6% | $5.9M-11.6% | ||
| $3.43M-39.8% | $3.5M-45.9% | $3.94M-36.6% | $5.79M-12.6% | $5.7M-22.6% | ||
| $5.97M-30.0% | $5.48M-23.9% | $6.03M-22.2% | $8.08M+5.8% | $8.53M+20.0% | ||
| $14.27M-32.7% | $16.92M-12.4% | $19.38M-4.5% | $21.22M+1.5% | $21.19M-4.6% | ||
| -$6.19M+49.7% | -$11.23M+13.0% | -$14.15M-0.7% | -$14.23M-18.9% | -$12.3M-0.2% | ||
| -64.1%+54.2pp | -153.8%-5.4pp | -207.2%-35.1pp | -167.2%-52.5pp | -118.3%-10.1pp | ||
| $1.44M-29.4% | $1.63M-29.3% | $1.73M-30.6% | $1.87M-27.9% | $2.03M-26.0% | ||
| -$4.75M+53.7% | -$9.6M+9.4% | -$12.42M-7.4% | -$12.36M-31.8% | -$10.26M-7.7% | ||
| —— | —— | —— | —— | —— | ||
| -$4.75M+53.7% | -$9.6M+9.4% | -$12.42M-7.4% | -$12.36M-31.8% | -$10.26M-7.7% | ||
| -49.2%+49.5pp | -131.5%-9.5pp | -181.8%-40.3pp | -145.3%-55.4pp | -98.8%-14.8pp | ||
| -$0.04+60.0% | -$0.09+10.0% | -$0.12-9.1% | -$0.12-33.3% | -$0.10-11.1% | ||
| -$5.14M+54.1% | -$10.15M+14.3% | -$13.08M-0.7% | -$13.13M-20.6% | -$11.2M-0.3% | ||
| -53.2%+54.5pp | -139.1%-2.8pp | -191.5%-32.4pp | -154.3%-49.9pp | -107.8%-9.4pp | ||
| -$6.19M+49.7% | -$11.23M+13.0% | -$14.15M-0.7% | -$14.23M-18.9% | -$12.3M-0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is MaxCyte's revenue?
- MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.
- Is MaxCyte profitable?
- MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.
- What are MaxCyte's profit margins?
- Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.
- What is MaxCyte's earnings per share?
- MaxCyte's diluted EPS over the trailing twelve months is $-0.37.
- Where does MaxCyte's income statement data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
